<?xml version="1.0" encoding="iso-8859-1"?>
<frameset>
<predicate lemma="develop">
<roleset id="develop.01" name="" wordnet="10">
<roles>
  <role n="0" descr="non-intentional theme
"/>
  <role n="1" descr="thing developed
"/>
  <role n="2" descr="end result
"/>
</roles>
<example src="MEDLINE" no="*1">
<text>
Three new mutations, two missense and one nonsense, were detected: (1) a C-to-T transition in codon 44 in exon 2 replacing a threonine by an isoleucine (T44I) was found in a late-onset symptomatic female patient but not in her asymptomatic mother; (2) a C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son developed acute neonatal onset of OTC deficiency; (3) a C-to-T transition in codon 320 (arginine) abolishing a TaqI recognition site and creating a new BclI site in exon 9 with generation of a stop codon (R320X) leading to premature termination in the enzyme.

</text>
       <arg n="0">whose son
</arg>
       <arg n="1">acute neonatal onset of OTC deficiency
</arg>
       <arg n="2">-
</arg>
<fdg>
1	Three	three	qn:&gt;3	@QN&gt; %&gt;N NUM CARD
2	new	new	attr:&gt;3	@A&gt; %&gt;N A ABS
3	mutations	mutation	subj:&gt;11	@SUBJ %NH N NOM PL
4	,	,
5	two	two		@QN&gt; %&gt;N NUM CARD
6	missense	missense	mod:&gt;3	@APP %NH &lt;?&gt; N NOM SG
7	and	and	cc:&gt;6	@CC %CC CC
8	one	one	qn:&gt;9	@QN&gt; %&gt;N NUM CARD
9	nonsense	nonsense	cc:&gt;6	@APP %NH N NOM SG
10	,	,
11	were	be	v-ch:&gt;12	@+FAUXV %AUX V PAST PL
12	detected	detect	main:&gt;0	@-FMAINV %VP EN
13	:	:
14	(	(
15	1	1	main:&gt;14	@NH %NH NUM CARD
16	)	)
17	a	a	det:&gt;19	@DN&gt; %&gt;N DET SG
18	C-to-T	c-to-t	attr:&gt;19	@A&gt; %&gt;N N NOM SG
19	transition	transition		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG	@APP %NH N 

NOM SG
20	in	in	mod:&gt;19	@&lt;NOM %N&lt; PREP
21	codon	codon	attr:&gt;22	@A&gt; %&gt;N N NOM SG
22	44	44	pcomp:&gt;20	@&lt;P %NH NUM CARD
23	in	in	mod:&gt;22	@&lt;NOM %N&lt; PREP
24	exon	exon	pcomp:&gt;23	@&lt;P %NH N NOM SG
25	2	2		@QN&gt; %&gt;N NUM CARD
26	replacing	replace		@-FMAINV %VA ING
27	a	a	det:&gt;28	@DN&gt; %&gt;N DET SG
28	threonine	threonine	obj:&gt;26	@OBJ %NH &lt;?&gt; N NOM SG
29	by	by	ha:&gt;26	@ADVL %EH PREP
30	an	an	det:&gt;31	@DN&gt; %&gt;N DET SG
31	isoleucine	isoleucine	pcomp:&gt;29	@&lt;P %NH &lt;?&gt; N NOM SG
32	(	(
33	T44I)	t44i)	subj:&gt;34	@SUBJ %NH N NOM SG
34	was	be	v-ch:&gt;35	@+FAUXV %AUX V PAST
35	found	find	obj:&gt;12	@-FMAINV %VP EN
36	in	in	loc:&gt;35	@ADVL %EH PREP
37	a	a	det:&gt;38	@DN&gt; %&gt;N DET SG
38	late-onset	late-onset	pcomp:&gt;36	@&lt;P %NH &lt;?&gt; N NOM SG
39	symptomatic	symptomatic	attr:&gt;40	@A&gt; %&gt;N A ABS
40	female	female	attr:&gt;41	@A&gt; %&gt;N N NOM SG
41	patient	patient	obj:&gt;35	@OBJ %NH N NOM SG
42	but	but		@CC %CC CC
43	not	not	neg:&gt;44	@ADVL %EH NEG-PART
44	in	in		@ADVL %EH PREP
45	her	she	attr:&gt;46	@A&gt; %&gt;N PRON PERS GEN SG3
46	asymptomatic	asymptomatic	attr:&gt;47	@A&gt; %&gt;N A ABS
47	mother	mother	pcomp:&gt;44	@&lt;P %NH N NOM SG
48	;	;
49	(	(
50	2	2	main:&gt;49	@NH %NH NUM CARD
51	)	)
52	a	a	det:&gt;54	@DN&gt; %&gt;N DET SG
53	C-to-T	c-to-t	attr:&gt;54	@A&gt; %&gt;N N NOM SG
54	transition	transition		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@PCOMPL-O %NH N NOM SG	@APP %NH N 

NOM SG
55	in	in	mod:&gt;54	@&lt;NOM %N&lt; PREP
56	codon	codon	pcomp:&gt;55	@&lt;P %NH N NOM SG
57	214	214		@QN&gt; %&gt;N NUM CARD
58	creating	create		@-FMAINV %VA ING
59	a	a	det:&gt;63	@DN&gt; %&gt;N DET SG
60	new	new	attr:&gt;61	@A&gt; %&gt;N A ABS
61	RsaI	rsai	attr:&gt;62	@A&gt; %&gt;N N NOM SG
62	recognition	recognition	attr:&gt;63	@A&gt; %&gt;N N NOM SG
63	site	site	obj:&gt;58	@OBJ %NH N NOM SG
64	in	in	mod:&gt;63	@&lt;NOM %N&lt; PREP
65	exon	exon	attr:&gt;66	@A&gt; %&gt;N N NOM SG
66	6	6	pcomp:&gt;64	@&lt;P %NH NUM CARD
67	and	and		@CC %CC CC
68	substituting	substitute		@&lt;P-FMAINV %VA ING	@-FMAINV %VA ING
69	tyrosine	tyrosine	obj:&gt;68	@OBJ %NH N NOM SG
70	for	for	phr:&gt;68	@ADVL %EH PREP
71	histidine	histidine	pcomp:&gt;70	@&lt;P %NH &lt;?&gt; N NOM SG
72	(	(
73	H214Y)	h214y)	subj:&gt;74	@SUBJ %NH N NOM SG
74	was	be	v-ch:&gt;75	@+FAUXV %AUX V PAST
75	identified	identify	cc:&gt;35	@-FMAINV %VP EN
76	in	in	loc:&gt;75	@ADVL %EH PREP
77	an	an	det:&gt;80	@DN&gt; %&gt;N DET SG
78	asymptomatic	asymptomatic	attr:&gt;79	@A&gt; %&gt;N A ABS
79	female	female	attr:&gt;80	@A&gt; %&gt;N N NOM SG
80	carrier	carrier	pcomp:&gt;76	@&lt;P %NH N NOM SG
81	whose	who	det:&gt;82	@DN&gt; %&gt;N DET WH GEN
82	son	son	subj:&gt;83	@SUBJ %NH N NOM SG
83	developed	develop	mod:&gt;80	@+FMAINV %VA V PAST
84	acute	acute	attr:&gt;85	@A&gt; %&gt;N A ABS
85	neonatal	neonatal	attr:&gt;86	@A&gt; %&gt;N A ABS
86	onset	onset	obj:&gt;83	@OBJ %NH N NOM SG
87	of	of	mod:&gt;86	@&lt;NOM-OF %N&lt; PREP
88	OTC	otc	attr:&gt;89	@A&gt; %&gt;N ABBR NOM SG
89	deficiency	deficiency	pcomp:&gt;87	@&lt;P %NH N NOM SG
90	;	;
91	(	(
92	3	3	main:&gt;91	@NH %NH NUM CARD
93	)	)
94	a	a	det:&gt;96	@DN&gt; %&gt;N DET SG
95	C-to-T	c-to-t	attr:&gt;96	@A&gt; %&gt;N N NOM SG
96	transition	transition		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@APP %NH N NOM SG
97	in	in	mod:&gt;96	@&lt;NOM %N&lt; PREP
98	codon	codon	pcomp:&gt;97	@&lt;P %NH N NOM SG
99	320	320	qn:&gt;101	@QN&gt; %&gt;N NUM CARD
100	(	(
101	arginine	arginine	mod:&gt;98	@NH %NH N NOM SG
102	)	)
103	abolishing	abolish		@&lt;P-FMAINV %VA ING
104	a	a	det:&gt;107	@DN&gt; %&gt;N DET SG
105	TaqI	taqi	attr:&gt;106	@A&gt; %&gt;N N NOM SG
106	recognition	recognition	attr:&gt;107	@A&gt; %&gt;N N NOM SG
107	site	site	obj:&gt;103	@OBJ %NH N NOM SG
108	and	and	cc:&gt;103	@CC %CC CC
109	creating	create	cc:&gt;103	@&lt;P-FMAINV %VA ING
110	a	a	det:&gt;113	@DN&gt; %&gt;N DET SG
111	new	new	attr:&gt;112	@A&gt; %&gt;N A ABS
112	BclI	bcli	attr:&gt;113	@A&gt; %&gt;N N NOM SG
113	site	site	obj:&gt;109	@OBJ %NH N NOM SG
114	in	in	mod:&gt;113	@&lt;NOM %N&lt; PREP
115	exon	exon	attr:&gt;116	@A&gt; %&gt;N N NOM SG
116	9	9	pcomp:&gt;114	@&lt;P %NH NUM CARD
117	with	with		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
118	generation	generation	pcomp:&gt;117	@&lt;P %NH N NOM SG
119	of	of	mod:&gt;118	@&lt;NOM-OF %N&lt; PREP
120	a	a	det:&gt;122	@DN&gt; %&gt;N DET SG
121	stop	stop	attr:&gt;122	@A&gt; %&gt;N N NOM SG
122	codon	codon	pcomp:&gt;119	@&lt;P %NH N NOM SG
123	(	(
124	R320X)	r320x)		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@APP %NH N NOM SG	@A&gt; %&gt;N N 

NOM SG
125	leading	lead		@&lt;P-FMAINV %VA ING	@-FMAINV %VA ING	@NH %NH N NOM SG	@SUBJ %NH N 

NOM SG	@APP %NH N NOM SG
126	to	to		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
127	premature	premature	attr:&gt;128	@A&gt; %&gt;N A ABS
128	termination	termination	pcomp:&gt;126	@&lt;P %NH N NOM SG
129	in	in	mod:&gt;128	@&lt;NOM %N&lt; PREP
130	the	the	det:&gt;131	@DN&gt; %&gt;N DET
131	enzyme	enzyme	pcomp:&gt;129	@&lt;P %NH N NOM SG
132	.     .
</fdg>
</example>
<example src="EMBO" no="*1">
<text>
Although Pin1 -/- mice have previously been shown to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.

</text>
       <arg n="0">mice
</arg>
       <arg n="1">-
</arg>
       <arg n="2">-
</arg>
       <arg n="M-MAN">normally
</arg>
<fdg>

1	Although	although		@CS %CS CS
2	Pin1	pin1	attr:&gt;3	@A&gt; %&gt;N N NOM SG
3	&amp;#8211;	&amp;#8211;		@NH %NH N NOM SG
4	/	/	
5	&amp;#8211;	&amp;#8211;	attr:&gt;6	@A&gt; %&gt;N N NOM SG
6	mice	mouse	subj:&gt;7	@SUBJ %NH N NOM PL
7	have	have	v-ch:&gt;9	@+FAUXV %AUX V PRES
8	previously	previously	tmp:&gt;10	@ADVL %EH ADV
9	been	be	v-ch:&gt;10	@-FAUXV %AUX EN
10	shown	show		@-FMAINV %VP EN
11	to	to	pm:&gt;12	@INFMARK&gt; %AUX INFMARK&gt;
12	develop	develop	cnt:&gt;10	@-FMAINV %VA V INF
13	normally	normally	man:&gt;12	@ADVL %EH ADV
14	(	(
15	Fujimori	fujimori	main:&gt;14	@APP %NH N NOM SG
16	et	et		@CC %CC CC
17	al.	al.		@NH %NH ABBR NOM SG	@APP %NH ABBR NOM SG	@A&gt; %&gt;N ABBR NOM SG	@&lt;NOM %N&lt; ABBR NOM SG
18	,	,
19	1999	1999		@NH %NH NUM CARD	@A&gt; %&gt;N NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
20	)	)
21	,	,
22	we	we	subj:&gt;23	@SUBJ %NH PRON PERS NOM PL1
23	have	have	v-ch:&gt;24	@+FAUXV %AUX V PRES
24	uncovered	uncover		@-FMAINV %VA EN
25	that	that	pm:&gt;27	@CS %CS CS
26	they	they	subj:&gt;27	@SUBJ %NH PRON PERS NOM PL3
27	display	display	obj:&gt;24	@+FMAINV %VA V PRES
28	a	a	det:&gt;29	@DN&gt; %&gt;N DET SG
29	range	range	obj:&gt;27	@OBJ %NH N NOM SG
30	of	of	mod:&gt;29	@&lt;NOM-OF %N&lt; PREP
31	cell	cell	attr:&gt;32	@A&gt; %&gt;N N NOM SG
32	proliferative	proliferative	attr:&gt;33	@A&gt; %&gt;N A ABS
33	abnormalities	abnormality	pcomp:&gt;30	@&lt;P %NH N NOM PL
34	,	,
35	including	include	man:&gt;27	@-FMAINV %VA ING
36	decreased	decreased	attr:&gt;37	@A&gt; %&gt;N A ABS
37	body	body	attr:&gt;38	@A&gt; %&gt;N N NOM SG
38	size	size	obj:&gt;35	@OBJ %NH N NOM SG
39	,	,
40	retinal	retinal	attr:&gt;41	@A&gt; %&gt;N A ABS
41	degeneration	degeneration	cc:&gt;38	@OBJ %NH N NOM SG
42	and	and	cc:&gt;41	@CC %CC CC
43	neurological	neurological	attr:&gt;44	@A&gt; %&gt;N A ABS
44	abnormalities	abnormality	cc:&gt;41	@OBJ %NH N NOM PL
45	.     .
</fdg>
</example>
<example src="EMBO" no="2">
<text>
Spinach sown in October develops into the rosette stage and grows through the end of November.

</text>
       <arg n="0">-
</arg>
       <arg n="1">Spinach sown in October
</arg>
       <arg n="2">[into]the rosette stage
</arg>
<fdg>
1	Spinach	spinach	subj:&gt;5	@SUBJ %NH N NOM SG
2	sown	sow	mod:&gt;1	@-FMAINV %VP EN
3	in	in	ha:&gt;2	@ADVL %EH PREP
4	October	october	pcomp:&gt;3	@&lt;P %NH N NOM SG
5	develops	develop	main:&gt;0	@+FMAINV %VA V PRES SG3
6	into	into	goa:&gt;5	@ADVL %EH PREP
7	the	the	det:&gt;9	@DN&gt; %&gt;N DET
8	rosette	rosette	attr:&gt;9	@A&gt; %&gt;N N NOM SG
9	stage	stage	pcomp:&gt;6	@&lt;P %NH N NOM SG
10	and	and	cc:&gt;5	@CC %CC CC
11	grows	grow	cc:&gt;5	@+FMAINV %VA V PRES SG3
12	through	through	ha:&gt;11	@ADVL %EH PREP
13	the	the	det:&gt;14	@DN&gt; %&gt;N DET
14	end	end	pcomp:&gt;12	@&lt;P %NH N NOM SG
15	of	of	mod:&gt;14	@&lt;NOM-OF %N&lt; PREP
16	November	november	pcomp:&gt;15	@&lt;P %NH N NOM SG
17	.     .
</fdg>
</example>
<example src="EMBO" no="3">
<text>
It is planted from September up to the end of October, develops into the rosette stage and keeps on growing until the end of November.

</text>
       <arg n="0">It
</arg>
       <arg n="1">-
</arg>
       <arg n="2">[into] the rosette stage
</arg>
<fdg>
1	It	it	subj:&gt;2	@SUBJ %NH PRON NOM SG3
2	is	be	v-ch:&gt;3	@+FAUXV %AUX V PRES SG3
3	planted	plant	main:&gt;0	@-FMAINV %VP EN
4	from	from	sou:&gt;3	@ADVL %EH PREP
5	September	september	pcomp:&gt;4	@&lt;P %NH N NOM SG
6	up	up		@ADVL %EH ADV
7	to	to		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
8	the	the	det:&gt;9	@DN&gt; %&gt;N DET
9	end	end	pcomp:&gt;7	@&lt;P %NH N NOM SG
10	of	of	mod:&gt;9	@&lt;NOM-OF %N&lt; PREP
11	October	october	pcomp:&gt;10	@&lt;P %NH N NOM SG
12	,	,
13	develops	develop	cc:&gt;3	@+FMAINV %VA V PRES SG3
14	into	into	goa:&gt;13	@ADVL %EH PREP
15	the	the	det:&gt;17	@DN&gt; %&gt;N DET
16	rosette	rosette	attr:&gt;17	@A&gt; %&gt;N N NOM SG
17	stage	stage	pcomp:&gt;14	@&lt;P %NH N NOM SG
18	and	and	cc:&gt;13	@CC %CC CC
19	keeps	keep	cc:&gt;13	@+FMAINV %VA V PRES SG3
20	on	on	phr:&gt;19	@ADVL %EH ADV
21	growing	grow	obj:&gt;19	@-FMAINV %VA ING
22	until	until	ha:&gt;21	@ADVL %EH PREP
23	the	the	det:&gt;24	@DN&gt; %&gt;N DET
24	end	end	pcomp:&gt;22	@&lt;P %NH N NOM SG
25	of	of	mod:&gt;24	@&lt;NOM-OF %N&lt; PREP
26	November	november	pcomp:&gt;25	@&lt;P %NH N NOM SG
27	.     .
</fdg>
</example>
</roleset>
</predicate>
</frameset>
